The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of TNF-, lactoferrin, IFN-, IL-1, serum amyloid-A (SAA), IL-6 and/or -defensin associated with infection or an immune response generally.

The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of TNF-a, lactoferrin, IFN-, IL-I , serum amyloid-A (SAA), IL-6 and/or -defensin associated with infection or an immune response generally.

The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of TNF-a, lactoferrin, IFN-, IL-I , serum amyloid-A (SAA), IL-6 and/or -defensin associated with infection or an immune response generally.

The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of TNF-a, lactoferrin, IFN-, IL-I , serum amyloid-A (SAA), IL-6 and/or -defensin associated with infection or an immune response generally.

Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.

Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.

This invention relates generally to products and methods using lunasin-enriched soy extract combined with Reliv Now? to reduce free fatty acid levels and increase leptin levels and adiponectin levels in plasma for the control of obesity, type 2 diabetes and metabolic syndrome. More specifically, the present invention relates to novel compositions comprising lunasin enriched soy extract and Reliv Now? formulations, methods of using these compositions in individuals for the control of obesity, type 2 diabetes and metabolic syndrome, and methods of making compositions comprising them.

This invention relates generally to products and methods using lunasin-enriched soy extract combined with Reliv Now? to reduce free fatty acid levels and increase leptin levels and adiponectin levels in plasma for the control of obesity, type 2 diabetes and metabolic syndrome. More specifically, the present invention relates to novel compositions comprising lunasin enriched soy extract and Reliv Now? formulations, methods of using these compositions in individuals for the control of obesity, type 2 diabetes and metabolic syndrome, and methods of making compositions comprising them.

This invention relates generally to products and methods using lunasin-enriched soy extract combined with Reliv Now? to reduce free fatty acid levels and increase leptin levels and adiponectin levels in plasma for the control of obesity, type 2 diabetes and metabolic syndrome. More specifically, the present invention relates to novel compositions comprising lunasin enriched soy extract and Reliv Now? formulations, methods of using these compositions in individuals for the control of obesity, type 2 diabetes and metabolic syndrome, and methods of making compositions comprising them.

Some variations provide a process of converting a cannabinoid into a purified cannabinoid derivative, comprising: providing a starting composition comprising a cannabinoid; providing a C.sub.9-C.sub.11 non-aromatic hydrocarbon solvent; introducing the starting composition and the solvent to a conversion reactor; chemically converting some, but not all, of the cannabinoid to a cannabinoid derivative, generating a reaction mixture containing unreacted cannabinoid; conveying the reaction mixture to a crystallization unit; cooling the reaction mixture to precipitate unreacted cannabinoid out of the reaction mixture, thereby generating a mother liquor containing the cannabinoid derivative; and isolating and recovering the cannabinoid derivative from the mother liquor. Systems configured to carry out the disclosed processes are also provided. This invention offers a large-scale solution to economically convert CBD to D9-THC, among many other example. The principles of the invention may be applied to the conversion of various cannabinoids and terpenes into derivative products.